Aclaris Therapeutics Inc. Common Stock (ACRS)
Stock · NASDAQ · Health Care
$3.28as of 10/16/2026
Price chart
Active signals
ACRS Signal Track Record
How signals performed across all stocks →What ACRS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +4.5% | 59% | October 2, 2026 |
| Bollinger Band Breakout | 25 | +0.7% | 52% | August 4, 2026 |
| Bollinger Band Breakdown | 21 | +6.2% | 57% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +6.0% | 62% | October 1, 2026 |
| Any 20-session window (baseline) | +2.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with n…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 69
- Website
- www.aclaristx.com/
Fundamentals
- 1-day range
- $3.64$3.94
- Market cap
- $850.55M
- P/E (trailing)
- —
- P/E (forward)
- -4.86
- EPS (trailing)
- $-0.59
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 2.65M
How Aclaris Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Aclaris Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
- AMPHAmphastar Pharmaceuticals Inc. Common Stock$25.87▼ 2.08%Market cap $873.48MP/E 14.15$16.65$29.52
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
- CLYMClimb Bio Inc. Common Stock$9.82▼ 9.99%Market cap $801.68MP/E —$1.64$18.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
| AMPH Amphastar Pharmaceuticals Inc. Common Stock | $873.48M | 14.15 | $25.87 | ▼ 2.08% | $16.65$29.52 |
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
| CLYM Climb Bio Inc. Common Stock | $801.68M | — | $9.82 | ▼ 9.99% | $1.64$18.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · 10/8/2026
- Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Yahoo · 9/15/2026
- What's going on in today's after hours sessionChartMill · 9/14/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Kolbeck Roland Wilhelm · August 1, 2026 · Option Exercise36.4K
- Kolbeck Roland Wilhelm · August 1, 2026 · Tax Withholding12.4K @ $5.2
- Humphries William D. · June 5, 2026 · Option Exercise11.6K
- Molineaux Christopher P. · June 5, 2026 · Option Exercise11.6K
- Mehra Anand · June 5, 2026 · Option Exercise11.6K
- GOWEN MAXINE · June 5, 2026 · Option Exercise11.6K
- Vincent Milano · June 5, 2026 · Option Exercise11.6K
- SCHIFF ANDREW N · June 5, 2026 · Option Exercise11.6K
- Humphries William D. · June 4, 2026 · Grant11.0K
- Humphries William D. · June 4, 2026 · Grant42.4K
- Molineaux Christopher P. · June 4, 2026 · Grant11.0K
- Molineaux Christopher P. · June 4, 2026 · Grant42.4K
- Mehra Anand · June 4, 2026 · Grant11.0K
- Mehra Anand · June 4, 2026 · Grant42.4K
- GOWEN MAXINE · June 4, 2026 · Grant11.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 106.74M
- Total value held
- $392.03M
- Institutional holders
- 132
- Unknown14.25M
- Unknown9.35M
- Unknown7.41M
- Unknown6.80M
- Unknown6.67M
- Unknown5.17M
- Unknown4.93M
- Unknown4.47M
- Unknown4.04M
- Unknown3.87M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ACRS Not Highlighted in Recent Pre‑Market Moves
In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.
ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.